New York, NY
Psychedelic Therapy clinics in New York
New York has 6 providers offering psychedelic therapy, with ketamine-assisted psychotherapy as the dominant nationwide option. Ketamine is FDA-approved as an anesthetic and Spravato (esketamine) is FDA-approved for treatment-resistant depression, while ketamine-assisted psychotherapy (KAP) is practiced off-label by licensed clinicians. In New York, ketamine-assisted psychotherapy is the only medically available psychedelic option. Psilocybin and MDMA remain Schedule I federally. Psilocybin is legal only in Oregon and Colorado under state programs. MDMA-assisted therapy was not approved by the FDA in August 2024 after a Complete Response Letter to Lykos Therapeutics. New York clinics commonly pair ketamine infusions or IM injections with therapy sessions, typical packages run 2,500 to 6,000 dollars for a six-session protocol, and Spravato is covered by many insurers when criteria are met. Psilocybin and MDMA remain federally illegal, and the FDA issued a Complete Response Letter to Lykos Therapeutics in August 2024 for MDMA-assisted therapy for PTSD. A reputable New York provider will screen for cardiovascular risk, psychiatric history, and concurrent medications before starting treatment.
Hudson Mind
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Psychedelic Therapy
Curated Mental Health
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Psychedelic Therapy
Regulatory context
A note on New York's psychedelic therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
S 3520 / Psilocybin Assisted Therapy (2023)
Proposed a state psilocybin therapy framework; pending. -
A 114 / Psychedelic Decriminalization (2023)
Proposed decriminalization of possession and use of psilocybin, MDMA, DMT, mescaline, and ibogaine; pending. -
New York Public Health Law Article 33
Mirrors federal scheduling and governs controlled substance prescribing; requires NY-specific practitioner registration.
New York enforces federal and state scheduling. The New York State Bureau of Narcotic Enforcement (BNE) requires practitioners to obtain a New York State Controlled Substance License in addition to federal DEA. The Office of Professional Medical Conduct oversees prescriber discipline. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth compliance. New York PMP (I-STOP) requires electronic prescribing for controlled substances.